anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a snore preventing composition which gives anions originated from tourmaline to a nostril, a neck part, etc. to suppress a snore.  &lt;P&gt;SOLUTION: This snore preventing composition is snore preventing tourmaline mineral powder for using snore preventing effect by bringing the composition directly or indirectly in contact with the skin, and is specified by mixing powdered tourmaline mineral as the effective component into the base material of an external skin drug. A base in a cream form, gel form, lotion form, or milky lotion form is used as the base material. A tourmaline mineral is powder with 2-300 micron of the average particle diameter. The tourmaline mineral is brought in directly or indirectly contact with the skin to use the snore preventing effect as a snore preventing method.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a gene transfer agent decomposable by enzymic actions after being incorporated into a cell.  &lt;P&gt;SOLUTION: The gene transfer agent is composed of a cationic gelatin in which a cationic polymer chain is introduced into the side chain of gelatin. A polyacrylamide-based polymer block chain as the cationic polymer chain is bound through an aromatic ring to an amino group of the gelatin. A polyplex is formed by electrostatically binding a negatively charged gene. Since the main chain is composed of the gelatin, the gene transfer agent is decomposed by the enzyme actions in vivo.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Described herein are systems and methods for calculating respiratory parameters based on thermal measurements. In one embodiment, a system includes an inward-facing head-mounted thermal camera (CAM) and a computer. CAM takes thermal measurements of a region below the nostrils (TH ROI ) of a user, and TH ROI  are indicative of the exhale stream. Optionally, CAM is located above the user&#39;s upper lip and less than 15 cm from the user&#39;s face, and CAM does not occlude any of the user&#39;s mouth and nostrils. The computer generates feature values based on TH ROI  and utilizes a model to calculate a respiratory parameter based on the feature values. The model was trained based on previous TH ROI  of the user taken during different days. Optionally, the respiratory parameter is indicative of the user&#39;s breathing rate. Optionally, the computer detects whether the user breathed primarily through the mouth or through the nose.
962,711. Coating particulate material. SMITH KLINE &amp; FRENCH LABORATORIES. Aug. 30, 1962 [Sept. 18, 1961], No. 33415/62. Heading B2B. Fine solid particles are coated by forming a dense phase fluidized bed of the particles, continuously withdrawing particles from the lower portion of the fluidized bed, passing the withdrawn particles through a nozzle with a gas to deagglomerate them and eject them upwards into a coating zone, spraying the particles in said zone with a liquid coating material and directing the coated particles falling under gravity into the upper portion of the fluidized bed. As shown, apparatus for carrying out the process comprises an upstanding coating chamber 6 having an open lower end, means 104 for exhausting gas from the upper portion of the coating chamber, a casing 4 for containing solids having its upper end in communication with the lower end of the coating chamber, the lower portion of the casing having a decreasing cross-sectional area as it extends downwards, a powder nozzle 14, extending upwards within the casing from a point adjacent the inner periphery of the lower portion of the casing, gas supply means 50 for introducing a jet of gas into the casing, to supply a flow of gas between the casing and the powder nozzle so as to form when the apparatus is in use a fluidized bed of solid particles 24 within the casing and to entrain solid particles from the fluidized bed into the powder nozzle for spraying upwards into the coating chamber 61, and a spray nozzle 78 in the coating chamber adapted to spray a liquid coating material on to the solid particles. Particles of drugs, foodstuffs or chemicals may be sprayed with liquefied waxes.
Compositions and methods of manufacture for producing a medicament composition capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus. The present invention relates to such compositions and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner such that sufficient drug is administered to produce precisely a desired effect. The invention also relates to manufacturing techniques that enable therapeutic agents to be incorporated into nondissolvable drug containment matrixes which are capable of releasing the drug within a patient&#39;s mouth. An appliance or holder is preferably attached to the drug containment matrix. Employing the present invention the drug may be introduced into the patient&#39;s bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the negative aspects of both of these methods. The nondissolvable drug containment matrix may include permeation enhancers to increase the drug absorption by the mucosal tissues of the mouth. The matrix composition may also include pH buffering agents to modify the salival pH thereby increasing the absorption of the drug through the mucosal tissues.
PCT No. PCT/GB93/01861 Sec. 371 Date May 4, 1995 Sec. 102(e) Date May 4, 1995 PCT Filed Sep. 3, 1993 PCT Pub. No. WO94/06477 PCT Pub. Date Mar. 31, 1994The present invention pertains to proteinaceous gas- or gas precursor-containing microbubble contrast agents for use in ultrasound and/or MR imaging, in which the protein matrix is crosslinked by reaction with a bifunctional aldehyde (e.g., a dialdehyde such as glutaraldehyde or an  alpha , beta -unsaturated aldehyde such as acrolein) in an aqueous medium at substantially neutral pH. The contrast agents exhibit improved in vivo and storage stabilities, particularly if the matrix is also reacted with a Schiff&#39;s base reducing agent such as a borohydride. Modification of the size distribution of such crosslinked proteinaceous gas-containing contrast agents, e.g. to reduce the mean size of the microbubbles, further enhances their stability and permits preparation of novel contrast agents having a particularly narrow microbubble size distribution.
The invention relates to 1,2,3-triazole containing chalcone derivatives as well as a preparation method and an application. The compounds are obtained by using 4&#39;-propargyloxy chalcone as a raw material and reacting 4&#39;-propargyloxy chalcone with different substituted azidomethylenebenzene on a benzene ring in the presence of a catalyst, namely an anhydrous cupric sulfate/sodium ascorbate system. The tyrosinase activities of the synthesized new compounds are tested. The experimental results show that the compounds 3b, 5b, 6b, 9a, 10b and 15b show certain tyrosinase inhibiting activities. The method is mild in reaction conditions and simple and direct in experimental procedures. The 1,2,3-triazole containing chalcone derivatives are applied to preparation of drugs or cosmetics for whitening the skin and treating hyperpigmentation diseases such as chloasma and the like.
This invention discloses a novel class of skincare products to remove iron in the skin and its preparation method. The core active components, termed as de-ironizing inducers (Dll), consist of a reducing agent and a precipitating agent. The reducing agent is selected from vitamin C, vitamin E, glutathione, vitamin A, vitamin D and their derivatives. The precipitating agent is chosen from calcium carbonate, pearl powder, magnesium carbonate, barium carbonate, calcium phosphate, magnesium phosphate, barium phosphate, calcium silicate, magnesium silicate, and barium silicate. Molar ratios of the reducing agent with the precipitating agent range from 1 :3-6 and the core components in the skin care product range from 5% to 10% w/w. The PH value of the skincare product is between 6.6 and 7.4. The skin care products can safely and effectively remove iron in the skin, which has been shown to accelerate skin&#39;s natural aging and photoaging.
PURPOSE:To provide the titled drug preparation effective for the remedy of thrombotic diseases, etc. by using dried urokinase as a main component, and compounding the component with a stabilizer composed of an inorganic salt and/ or an organic acid salt and albumin. CONSTITUTION:The objective dried urokinase preparation is obtained by using dried urokinase as a main component, and compounding a stabilizer containing 30-50mg of albumin and 10-20mg of an inorganic salt and/or organic acid salt per 100,000-30,000 IU of urokinase. The combined use of the components results in the synergistic stabilization of the dried urokinase. Since the stabilizer is effective also for the prevention of the decomposition of urokinase by freeze-drying, it is preferable to add the stabilizer prior to the freeze-drying of urokinase. The albumin is preferably those derived from human, and its purity is preferably &gt;=80% determined by electrophoresis.
PURPOSE:To obtain an antiallergic fat and oil composition having extremely inhibitory action on allergy, orally administrable and comprising fats and oils containing a specific fatty acid as a constituent fatty acid and a tea extract as active ingredients. CONSTITUTION:Fats and oils containing a fatty acid selected from alpha-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid as a constituent fatty acid are blended with a tea extract to give the objective substance. The objective substance contains &gt;=20wt.% fatty acid and 0.02 to 2wt.% tea extract. The objective substance can be administered in capsule, tablet, emulsion, injection, etc., or may be administered in the form of food by blending the substance with a salad oil, margarine, etc. A does is 0.5 to 30g per adult daily. Fats and oils having high content of unsaturated fatty acid have poor stability. The tea extract is effective as an antioxidant for fats and oils containing highly unsaturated fatty acid and antiallergic properties are enhanced by addition of the tea extract.
PURPOSE:A carcinostatic agent comprising a substance obtained by bonding apoprotein of high polymer polypeptide carcinostatic agent to chromophore of high polymer polypeptide carcinostatic agent in a specific ratio as an active ingredient. CONSTITUTION:A fixed amount of apoprotein is dissolved in water. On the other hand, a fixed amount of chromophore is dissolved in a water-miscible organic solvent (e.g., methanol). Then, both the solutions are blended in such a way that they are subjected to hydrogen bond and/or hydrophobic bond in a ratio of 1 apoprotein molecule to &gt;=11 chromophore molecules, the organic solvent is removed and the resultant substance is lyophilized. The prepared lyophilized powder is redissolved in water. If an insoluble substance exists, it is removed by centrifugation and a water-soluble fraction is isolated and purified to give a bond substance. A carcinostatic agent having improved toxicity and carcinostatic spectrum, containing it as an active ingredient, is obtained.
The marijuana-based investigation medical product (MB-IMP) in this study is 23 parts CBD and 1 part THC. The placebo is medium chain triglyceride oil. MB-IMP or placebo will be taken orally. DSM-5 diagnosis of autism spectrum disorder will be confirmed with Autism Diagnostic Observation Schedule, version 2, and review of medical records. History of psychosis, suicidality, cardiac or hepatocellular issues may be exclusionary. The participant must have a study partner who will complete observational assessments regarding the participant\&#39;s behavior.

The screening period is 3 weeks to allow for lab results and medical records to be obtained. The active phase of the study (on drug or placebo) is 8 weeks, and their will be one follow-up visit after 14 days off drug.
PURPOSE: A dental clinic management method and system are provided to support exact and comfortable counseling and treatment using network chair, which has an oral camera and a monitor. CONSTITUTION: The system consists of a chair system, communication networks and medical insurance company. The chair system has not only input and output systems but also communication devices like modem and a control device. During treatment a dentist can inquiry the patient&#39;s treatment record and oral image data and after treatment the system automatically request the dentist fee to the medial insurance company. The chair has dental apparatuses, an oral camera(130), a keyboard(140), a monitor(150) and a dental server(110), which contains a processor(111), communication devices(115) and storage(120). The LCD panel and the monitor can be installed separately or unitedly like there is a monitor in the front side and an LCD panel in the rear side or vice versa. The camera is installed with a light to take a picture with low illumination. When a patient sit on the chair, the dentist can inquiry the record. If there is record or picture, the system displays them on the monitor. According to the record, the dentist consults the treatment and treats the patient. After treatment, the system makes an appointment automatically and the patient select available time.
To provide RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes as well as methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.SOLUTION: There is provided a double-stranded RNAi agent for inhibiting expression of hepatitis B virus (HBV) in a cell. The double-stranded RNAi agent comprises a sense strand and an antisense strand forming a double- stranded region. The sense strand comprises a specific nucleotide sequence. Substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides. The sense strand is conjugated to a ligand attached at the 3&#39;-terminus. The ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.SELECTED DRAWING: Figure 1
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for safely delivering ≥1 small interfering RNAs (siRNAs) to a eukaryotic cell.  &lt;P&gt;SOLUTION: The method for delivering the siRNAs to the eukaryotic cell using bacteria is provided. A method for using the bacteria for modulating gene expression in the eukaryotic cell using RNA interference and a method for treating cancers from cell proliferation disorders are also provided. The bacteria contain ≥1 siRNAs or ≥1 DNA molecules encoding ≥1 siRNAs. A vector used with the bacteria for causing the RNA interference in the eukaryotic cell is also provided by the invention.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A binding protein for Corticotropin Releasing Factor (CRF) is isolated from human plasma and partially sequenced. Using degenerate oligonucleotides based upon certain partial sequences of the isolated protein, the complete sequence for the 322-residue human precursor protein, termed CRF-BP, is deduced, which is believed to circulate in the plasma as an N-terminally shortened 298-residue mature protein. The homologous 322-residue sequence of the rat precursor protein is separately deduced. These proteins are produced recombinantly, and they are useful in the reduction of high ACTH levels in mammals caused by excess CRF and can be used to treat Cushing&#39;s Disease. They are also particularly useful in combating pituitary tumors which produce CRF and in modulating the various actions of CRF on the pituitary, the brain, the immune system and gastrointestinal blood flow. The proteins can also be used to raise blood pressure and combat hypotension in this manner.  Antibodies to the proteins may be employed in diagnostic assays and in purification of the protein; they are also useful to counteract the biological effect of CRF-BPs.
Magazines that include a supporting member such as a strap, rod or chamber and one or preferably a plurality of portable medicament cases that each include a medicament provided in a package. Each case has first and second housing members that are configured to form a medicament package receiving cavity when joined together. The housing members mate together in a sealed configuration that prevents moisture or contaminants from entering into the cavity. The magazines are configured for containing a plurality of medicament cases for administration of medicaments to a group of people. Also included is a method of administering medications to mass casualties of multiple persons that are in need thereof. The medicaments are rapidly disintegratable and can include a dye that stains the person&#39;s mouth so that medical personnel can determine who has been treated with the medicament.
&lt;P&gt;PROBLEM TO BE SOLVED: To extract an estrogenic active substance in an enough amount from a food material, and to provide a health food, a pharmaceutical or the like, by using the extracted substance.  &lt;P&gt;SOLUTION: This estrogenic active substance is extracted from an edible mushroom, a mycelium of an edible mushroom formative fungus, a culture solution of the mycelium of the edible mushroom formative fungus, etc. The mushroom is selected from Pleurotus eryngii, Flammulina velutipes, Pleurotus pulmonarius, Panellus serotinus, Grifola frondosa, and Pleurotus abalonus. The Pleurotus eryngii is especially preferably selected as the mushroom. The health food, the pharmaceutical or the like contains the estrogenic active substance extracted from the edible mushroom.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technology for improving skin adhesion maintenance in a skin external preparation containing a powder of oil-in-water type emulsion dosage form.  &lt;P&gt;SOLUTION: The skin external preparation comprises (1) 0.05-5 mass% of an acyl lactic acid and/or its salt, (2) 0.1-10 mass% of an acylated polyglycerin, (3) 0.01-1 mass% of a sulfate-based anionic surfactant and (4) a powder. The powder is a powder having a hydroxyapatite-containing coating layer on the surface. The acyl lactic acid is preferably stearoyl lactic acid. The powder has the surface preferably subjected to at least one kind of a surface treatment selected from an N-acylamino acid salt coating treatment, a methylhydrogenpolysiloxane baking treatment and a silane coupling treatment with an alkylalkoxysilane.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
<br><b>Introduction:</b> The early detection and diagnosis of dementia are of key importance in treatment, slowing disease progression, or suppressing symptoms. The possible role of changes in the sense of smell is considered with regard to potential markers for early detection of Alzheimer's disease (AD).</br> <br><b>Materials and methods:</b> A literature search was conducted using the electronic databases PubMed, Scopus, and Web of Science between May 30, 2022 and August 2, 2022. The term "dementia" was searched with keyword combinations related to olfaction.</br> <br><b>Results:</b> A total of 1,288 records were identified through the database search. Of these articles, 49 were ultimately included in the analysis. The results showed the potential role of changes in the sense of smell as potential biomarkers for early detection of AD. Multiple studies have shown that olfactory impairment may be observed in patients with AD, PD, MCI, or other types of dementia. Even though smell tests are able to detect olfactory loss caused by neurodegenerative diseases, they cannot reliably distinguish between certain diseases.</br> <br><b>Conclusions:</b> In individuals with cognitive impairment or neurodegenerative diseases, olfactory assessment has repeatedly been reported to be used for early diagnosis, but not for differential diagnosis.</br&gt.
PURPOSE:To obtain a liquid hair cosmetic containing an odd carbon-chain fatty acid, an ester of an even carbon-chain fatty acid and an alcohol. CONSTITUTION:The objective cosmetic contains 0.1-10wt.% of a fatty acid having a 3-25C carbon chain of odd carbon number or its derivative (e.g. pentadecanoic acid), 0.5-50wt.% of a mono- or diester of a fatty acid having a carbon chain of even carbon number (e.g. ethyl undecylenoate) and &gt;=40wt.% of a lower alcohol. In addition to the above components, the cosmetic is further compounded properly with surfactants, oils, vitamins, hormones, keratolytic agent, disinfectant, etc. The weight ratio of the odd-carbon chain fatty acid to the even carbon number fatty acid ester is preferably 10/1 to 1/40.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for inducing immune response, especially by administering a dendritic cell (DC) capable of inducing antitumor immune response, or by administering the DC to an animal including a human being, to provide an agent for inducing the immune response, usable for the method for inducing the immune response, and to provide a kit for inducing the immune response.  &lt;P&gt;SOLUTION: An apoptosis-induced tumor cell (ATC) is haptenized by using trinitrophenyl, and the haptenized ATC is combined with an IgG antihapten antibody. The obtained ATC-hapten-IgG antihapten antibody complex (ATC-IC) is cultured with the DC. As a result, the ATC-IC is efficiently incorporated into the DC through FcγR expressed on the DC, and the mature of the DC is induced. When a mouse is immunized by the DC having the ATC-IC incorporated therein, CTL is effectively activated, and a strong antitumor immune response is induced.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a gene arranged to express a reporter protein in a way dependent on endoplasmic reticulum stress, a recombinant expression vector including the gene, a transformant transformed by the expression vector, a method for screening a medical agent inhibiting or activating the endoplasmic reticulum stress response by using the transformant, and to provide a transgenic organism obtained by transducing the gene.  &lt;P&gt;SOLUTION: The invention relates to the gene expressing the reporter protein dependent on endoplasmic reticulum stress, containing a base sequence encoding a fusion gene comprising a gene receiving a frame-switch type splicing dependent on the endoplasmic reticulum stress and a gene of a reporter protein, wherein the sequence has one or more bases deleted, substituted or inserted. The invention also relates to the recombinant expression vector including the gene and the target gene to be expressed. The transformant transformed by the expression vector. The screening for medical agent using them. The transgenic organism obtained by transducing the gene.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI